Skip to main content

PET/CT in Gynaecological Malignancies

  • Chapter
  • First Online:
  • 837 Accesses

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

This chapter covers the use of PET/CT in gynaecological cancers concentrating on cervical, endometrial and ovarian cancers. The technical aspects and limitations of PET/CT specific to gynaecological malignancies are highlighted.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Barwick TD, Taylor A, Rockall A. Functional imaging to predict tumor response in locally advanced cervical cancer. Curr Oncol Rep. 2013;15(6):549–58.

    Article  PubMed  Google Scholar 

  2. Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010;101(6):1471–9.

    Article  CAS  PubMed  Google Scholar 

  3. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET data collection project. Gynecol Oncol. 2009;112(3):462–8.

    Article  CAS  PubMed  Google Scholar 

  4. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164–74.

    Article  PubMed  Google Scholar 

  5. Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, Chi DS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol. 2007;106(1):177–80.

    Article  CAS  PubMed  Google Scholar 

  6. Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404.

    Article  PubMed  Google Scholar 

  7. Kakhki VR, Shahriari S, Treglia G, Hasanzadeh M, Zakavi SR, Yousefi Z, Kadkhodayan S, Sadeghi R. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Int J Gynecol Cancer. 2013;23(9):1536–43.

    Article  PubMed  Google Scholar 

  8. Kang S, Kim SK, Chung DC, Seo SS, Kim JY, Nam BH, Park SY. Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis. J Nucl Med. 2010;51(3):360–7.

    Article  PubMed  Google Scholar 

  9. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, Sugimura K. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35(10):1912–20.

    Article  PubMed  Google Scholar 

  10. Kitajima K, Suzuki K, Senda M, Kita M, Nakamoto Y, Onishi Y, Maeda T, Yoshikawa T, Ohno Y, Sugimura K. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011;32(7):549–53.

    Article  PubMed  Google Scholar 

  11. MAPPING study. Available at http://www.cancerresearchuk.org/cancer-help/trials/a-study-comparing-mri-scan-pet-ct-scan-cervical-womb-cancer-mapping.

  12. Meads C, Auguste P, Davenport C, Malysiak S, Sundar S, Kowalska M, Zapalska A, Guest P, Thangaratinam S, Martin-Hirsch P, Borowiack E, Barton P, Roberts T, Khan K. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. Health Technol Assess. 2013;17(12):1–323.

    Article  Google Scholar 

  13. National Comprehensive Cancer Network (NCCN) guidelines for cervical cancer. 2010. Available at http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.

  14. Royal College of Radiologists. RCR PET guidelines. 2012. Available at http://www.rcr.ac.uk/docs/radiology/pdf/BFCR(12)3_PETCT.pdf.

  15. Rockall A, Munari A, Avril N. New ways of assessing ovarian cancer response: metabolic imaging and beyond. Cancer Imaging. 2012;12(09):310–4.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C, Bergstrom D, Sala E, Sarker SJ, Mcneish IA, Brenton JD. Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. Clin Cancer Res. 2014;20(10):2751–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Salem A, Salem AF, Al-Ibraheem A, Lataifeh I, Almousa A, Jaradat I. Evidence for the use PET for radiation therapy planning in patients with cervical cancer: a systematic review. Hematol Oncol Stem Cell Ther. 2011;4(4):173–81.

    Article  CAS  PubMed  Google Scholar 

  18. Schwarz JK, Lin LL, Siegel BA, Miller TR, Grigsby PW. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2008;72(5):1502–7.

    Article  PubMed  Google Scholar 

  19. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298(19):2289–95.

    Article  CAS  PubMed  Google Scholar 

  20. Scottish intercollegiate guidelines network. Management of cervical cancer. (SIGN guideline no 99). 2008. Available at: http://www.sign.ac.uk/guidelines/fulltext/99/index.html.

  21. Scottish intercollegiate guidelines network. Management of epithelial ovarian cancer. (SIGN guideline no 135). 2013. Available at: http://www.sign.ac.uk/guidelines/fulltext/135/index.html.

  22. Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ. 2008;178(7):855–62.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Walentowicz-Sadlecka M, Malkowski B, Walentowicz P, Sadlecki P, Marszalek A, Pietrzak T, Grabiec M. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Biomed Res Int. 2014;7:2014. doi:10.1155/2014/234813.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tara Barwick .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Khan, S.R., Barwick, T. (2016). PET/CT in Gynaecological Malignancies. In: Barwick, T., Rockall, A. (eds) PET/CT in Gynecological Cancers. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-29249-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29249-6_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29247-2

  • Online ISBN: 978-3-319-29249-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics